Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
- PMID: 20526439
- PMCID: PMC2878955
- DOI: 10.2147/tcrm.s7245
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
Abstract
Glucocorticoids are essential in treating many disorders and they are widely used in spite of their negative impact on the skeletal system. As bisphosphonates reduce bone resorption through their action on osteoclasts, they play an important role in management of glucocorticoid-induced osteoporosis. Unlike other bisphosphonates, zoledronic acid is given by intravenous infusion and it has a potential advantage of increasing the compliance and adherence of patients when it is given 5 mg once a year. However, this treatment modality seems to be associated with more adverse events than oral administrations, and further studies with longer follow-up periods must be conducted to determine the safety and cost-effectiveness of long-term treatment with zoledronic acid.
Keywords: bisphosphonates; glucocorticoids; osteoporosis; zoledronic acid.
Figures
Similar articles
-
Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates.Eur J Hosp Pharm. 2019 Jan;26(1):4-9. doi: 10.1136/ejhpharm-2017-001258. Epub 2017 Sep 20. Eur J Hosp Pharm. 2019. PMID: 31157088 Free PMC article. Review.
-
Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27. Ann Pharmacother. 2008. PMID: 18505912
-
The role of zoledronic acid in the management of osteoporosis.Clin Rheumatol. 2010 Oct;29(10):1079-84. doi: 10.1007/s10067-010-1486-3. Epub 2010 Jun 11. Clin Rheumatol. 2010. PMID: 20544246 Review.
-
[Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].Reumatismo. 2009 Jan-Mar;61(1):54-64. doi: 10.4081/reumatismo.2009.54. Reumatismo. 2009. PMID: 19370189 Italian.
-
Clinical efficacy and safety of zoledronic acid in osteoporosis and Paget's bone disease.Expert Rev Endocrinol Metab. 2009 Sep;4(5):405-415. doi: 10.1586/eem.09.23. Expert Rev Endocrinol Metab. 2009. PMID: 30736183
Cited by
-
Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review.World J Mens Health. 2020 Apr;38(2):151-163. doi: 10.5534/wjmh.190044. Epub 2019 May 2. World J Mens Health. 2020. PMID: 31081297 Free PMC article. Review.
-
Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy.Cancer Immunol Immunother. 2012 Apr;61(4):535-47. doi: 10.1007/s00262-011-1121-4. Epub 2011 Oct 15. Cancer Immunol Immunother. 2012. PMID: 22002242 Free PMC article.
References
-
- Kino T. Tissue glucocorticoid sensitivity: beyond stochastic regulation on the diverse actions of glucocorticoids. Horm Metab Res. 2007;39(6):420–424. - PubMed
-
- Viegas LR, Hoijman E, Beato M, Pecci A. Mechanisms involved in tissue-specific apopotosis regulated by glucocorticoids. J Steroid Biochem Mol Biol. 2008;109(3–5):273–278. - PubMed
-
- Baxter JD, Rousseau GG. Glucocorticoid Hormone Action: an overview. Monogr Endocrinol. 1979;(12):1–24. - PubMed
-
- Cole TJ, Blendy JA, Monaghan AP, et al. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 1995;9(13):1608–1621. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials